SS&C Technologies Holdings, Inc. (SSNC)
NASDAQ: SSNC · Real-Time Price · USD
84.20
-1.28 (-1.50%)
At close: Aug 1, 2025, 4:00 PM
84.23
+0.03 (0.04%)
After-hours: Aug 1, 2025, 4:10 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 8 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $97.13, which forecasts a 15.36% increase in the stock price over the next year. The lowest target is $88 and the highest is $108.
Price Target: $97.13 (+15.36%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| DA Davidson | DA Davidson | Strong Buy Maintains $98 → $102 | Strong Buy | Maintains | $98 → $102 | +21.14% | Jul 25, 2025 |
| UBS | UBS | Strong Buy Maintains $105 → $108 | Strong Buy | Maintains | $105 → $108 | +28.27% | Jul 24, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $90 → $95 | Strong Buy | Maintains | $90 → $95 | +12.83% | Jul 24, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $86 → $94 | Hold | Maintains | $86 → $94 | +11.64% | Jul 24, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $75 → $88 | Hold | Maintains | $75 → $88 | +4.51% | Jul 24, 2025 |
Financial Forecast
Revenue This Year
6.34B
from 5.88B
Increased by 7.72%
Revenue Next Year
6.66B
from 6.34B
Increased by 5.10%
EPS This Year
5.98
from 3.00
Increased by 99.18%
EPS Next Year
6.59
from 5.98
Increased by 10.21%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.5B | 6.9B | 7.3B | ||
| Avg | 6.3B | 6.7B | 7.0B | ||
| Low | 6.1B | 6.3B | 6.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.3% | 9.6% | 9.5% | ||
| Avg | 7.7% | 5.1% | 4.6% | ||
| Low | 3.2% | -0.4% | -1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.22 | 7.13 | 7.50 | ||
| Avg | 5.98 | 6.59 | 7.08 | ||
| Low | 5.64 | 6.11 | 6.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 107.2% | 19.3% | 13.9% | ||
| Avg | 99.2% | 10.2% | 7.5% | ||
| Low | 87.8% | 2.2% | -0.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.